OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price, Price Target & More

$16.05 -0.59 (-3.55 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$16.64
Today's Range$16.05 - $16.80
52-Week Range$12.00 - $25.35
Volume200 shs
Average Volume5,413 shs
Market Capitalization$3.87 billion
P/E Ratio15.29
Dividend Yield1.32%
Beta-1.09

About Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals logoHikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment's principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment's principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment's principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:HKMPF
CUSIPN/A
Phone44-20-7399-2760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio15.29
Forward P/E Ratio17.26
P/E Growth5.78

Sales & Book Value

Annual Sales$1.94 billion
Price / Sales2.00
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees8,500
Outstanding Shares240,870,000

How to Become a New Pot Stock Millionaire

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, June, 13th 2018. View Earnings Estimates for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News articles about HKMPF stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 0.05 on Accern's scale. They also assigned media headlines about the company an impact score of 49.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $16.05.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of $3.87 billion and generates $1.94 billion in revenue each year. Hikma Pharmaceuticals employs 8,500 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]


MarketBeat Community Rating for Hikma Pharmaceuticals (HKMPF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Hikma Pharmaceuticals in the last 12 months. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.751.751.752.00
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Consensus Price Target History

Price Target History for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/10/2018Jefferies GroupDowngradeHold -> UnderperformView Rating Details
8/22/2017Goldman SachsDowngradeBuy -> NeutralView Rating Details
8/8/2017Morgan StanleyReiterated RatingEqual WeightView Rating Details
5/19/2017Numis SecuritiesReiterated RatingBuy -> AddView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Dividends

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Dividend Information

Hikma Pharmaceuticals pays an annual dividend of $0.22 per share, with a dividend yield of 1.37%. Hikma Pharmaceuticals pays out 20.95% of its earnings out as a dividend.
Annual Dividend:$0.22
Dividend Yield:1.37%
Payout Ratio:20.95% (Trailing 12 Months of Earnings)
23.66% (Based on This Year's Estimates)
22.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Hikma Pharmaceuticals (OTCMKTS HKMPF) Insider Trading and Institutional Ownership History

Insider Trading History for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals (OTCMKTS HKMPF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Hikma Pharmaceuticals (OTCMKTS HKMPF) News Headlines

Source:
DateHeadline
ValuEngine Upgrades Hikma Pharmaceuticals (HKMPF) to BuyValuEngine Upgrades Hikma Pharmaceuticals (HKMPF) to Buy
www.americanbankingnews.com - April 15 at 7:48 PM
Hikma Pharmaceuticals (HKMPF) Equal Weight Rating Reaffirmed at Morgan StanleyHikma Pharmaceuticals' (HKMPF) Equal Weight Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - April 14 at 10:20 AM
Comparing Hikma Pharmaceuticals (HKMPF) and Bankinter (BKNIY)Comparing Hikma Pharmaceuticals (HKMPF) and Bankinter (BKNIY)
www.americanbankingnews.com - April 6 at 3:21 PM
Hikma Pharmaceuticals (HKMPF) Given Consensus Rating of "Hold" by BrokeragesHikma Pharmaceuticals (HKMPF) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 3 at 1:48 AM
Hikma Pharmaceuticals (HKMPF) Upgraded to "Hold" at Zacks Investment ResearchHikma Pharmaceuticals (HKMPF) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 2 at 6:58 PM
Zacks Investment Research Upgrades Hikma Pharmaceutic (HKMPF) to HoldZacks Investment Research Upgrades Hikma Pharmaceutic (HKMPF) to Hold
www.americanbankingnews.com - March 24 at 2:13 PM
FY2018 Earnings Forecast for Hikma Pharmaceutic (HKMPF) Issued By Jefferies GroupFY2018 Earnings Forecast for Hikma Pharmaceutic (HKMPF) Issued By Jefferies Group
www.americanbankingnews.com - March 19 at 4:02 AM
Hikma Pharmaceutic (HKMPF) Upgraded to "Hold" at Zacks Investment ResearchHikma Pharmaceutic (HKMPF) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 18 at 12:38 PM
Equities Analysts Offer Predictions for Hikma Pharmaceutics FY2022 Earnings (HKMPF)Equities Analysts Offer Predictions for Hikma Pharmaceutic's FY2022 Earnings (HKMPF)
www.americanbankingnews.com - March 16 at 4:20 PM
Hikma Pharmaceutic (HKMPF) Given Consensus Rating of "Hold" by AnalystsHikma Pharmaceutic (HKMPF) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 9 at 1:42 AM
Hikma Pharmaceutic (HKMPF) Receives Average Rating of "Hold" from AnalystsHikma Pharmaceutic (HKMPF) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 12 at 1:48 AM
New Strong Sell Stocks for February 9thNew Strong Sell Stocks for February 9th
finance.yahoo.com - February 9 at 8:30 AM
Hikma Pharmaceuticals Plc (HKMPF) Given Average Rating of "Hold" by BrokeragesHikma Pharmaceuticals Plc (HKMPF) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 18 at 2:08 AM
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy at ValuEngineHikma Pharmaceuticals (HKMPF) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - January 13 at 7:14 PM
FY2017 Earnings Forecast for Hikma Pharmaceuticals Plc Issued By Jefferies Group (HKMPF)FY2017 Earnings Forecast for Hikma Pharmaceuticals Plc Issued By Jefferies Group (HKMPF)
www.americanbankingnews.com - January 11 at 8:04 AM
Hikma Pharmaceuticals (HKMPF) Lowered to "Underperform" at Jefferies GroupHikma Pharmaceuticals (HKMPF) Lowered to "Underperform" at Jefferies Group
www.americanbankingnews.com - January 10 at 10:42 AM
Hikma Signs Licensing Deal With Celltrion For Truxima; Stcok Up - Quick FactsHikma Signs Licensing Deal With Celltrion For Truxima; Stcok Up - Quick Facts
www.rttnews.com - December 19 at 10:42 AM
Jefferies Group Weighs in on Hikma Pharmaceuticals Plcs FY2017 Earnings (HKMPF)Jefferies Group Weighs in on Hikma Pharmaceuticals Plc's FY2017 Earnings (HKMPF)
www.americanbankingnews.com - December 5 at 8:14 AM
Hikma Pharmaceuticals Partakes In Funding Round For PrognosHikma Pharmaceuticals Partakes In Funding Round For Prognos
www.morningstar.co.uk - November 30 at 4:16 PM
Hikma Pharmaceuticals Plc (HKMPF) Receives Consensus Rating of "Hold" from BrokeragesHikma Pharmaceuticals Plc (HKMPF) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 29 at 1:38 AM

SEC Filings

Hikma Pharmaceuticals (OTCMKTS:HKMPF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Hikma Pharmaceuticals (OTCMKTS HKMPF) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.